Metastatic prostate cancer is a cancer of the prostate gland that has spread to other parts of the body, such as lymph nodes. A recent study (CARD) suggested that cabazitaxel significantly improved the progression-free and overall survival in metastatic prostate cancer patients when compared with abiraterone or enzalutamide. This study aims to assess the quality-of-life outcomes after the treatment of metastatic prostate cancer with cabazitaxel or abiraterone or enzalutamide.

The CARD study was a multicenter, open-label, phase-4, randomized study that included a total of 255 patients with confirmed metastatic castration-resistant prostate cancer. The patients were randomly assigned in a 1:1 ratio to receive cabazitaxel or abiraterone or enzalutamide. The primary outcome of the study was pain response, along with patient-reported outcomes.

At a median follow-up of 9.2 months, pain response was observed in 46% of the patients who received cabazitaxel, as compared with 19% in patients who received abiraterone or enzalutamide. The median time-to-pain progression and time-to-symptomatic skeletal events were not estimable in the cabazitaxel group, as compared with 8.5 months and 16.7 months in the abiraterone or enzalutamide group.

The research concluded that treatment with cabazitaxel improved pain response, time-to-pain progression, and time-to-symptomatic skeletal events in patients with metastatic prostate cancer.